A novel antimicrobial peptide <scp>M1</scp>‐8 targets the lysosomal pathway to inhibit autolysosome formation and promote apoptosis in liver cancer cells

Jiali Zeng, Jian Wang, Jibin Wu, Rui Deng, Lun Zhang, Qingru Chen, Jie Wang, Xiaobao Jin, Shuiqing Gui, Yinghua Xu, Xuemei LuJournal of Cellular and Molecular Medicine 2023 · DOI

TL;DR

Researchers have developed a novel antimicrobial peptide, M1-8, derived from Musca domestica cecropin, that effectively inhibits liver cancer cell growth. M1-8 works by disrupting lysosomal function, specifically blocking the fusion of autophagosomes and lysosomes, which ultimately triggers cancer cell apoptosis. This discovery offers a promising new therapeutic avenue for liver cancer treatment.

What Problem Does This Paper Address?

Liver cancer, particularly hepatocellular carcinoma (HCC), remains a significant global health challenge with limited treatment options and poor patient survival rates. Conventional chemotherapeutic agents often prove inefficient and lead to drug resistance. There's a critical need for novel therapeutic strategies that can overcome these limitations and offer enhanced efficacy. Autophagy, a cellular process involving the degradation of cellular components via lysosomes, plays a complex role in tumor growth and survival. While autophagy can be a survival mechanism for cancer cells, its dysregulation, particularly at the lysosomal level, can also lead to cell death. This paper investigates a new peptide's potential to exploit this vulnerability in liver cancer.

Methods

The study employed a multi-faceted approach to investigate the effects of M1-8:

  • Cell Viability Assays (MTT): Standard MTT assays were used to assess the cytotoxic effects of M1-8 on HepG2 (cancerous) and normal liver cell lines (L02, Chang liver).
  • Cell Migration and Invasion Assays: Scratch assays were used to measure cell migration, while transwell assays (with and without Matrigel) were employed to evaluate cell invasion capabilities.
  • Apoptosis Assays:
    • Flow Cytometry (Annexin V-FITC/PI): This technique quantifies apoptotic cells by detecting phosphatidylserine exposure and membrane integrity.
  • Hoechst 33258 Staining: Used to visualize nuclear morphology changes indicative of apoptosis (fragmentation, condensation).
  • JC-1 Staining: Assesses mitochondrial membrane potential, an early indicator of apoptosis.
  • Western Blot: Analyzed the expression levels of key apoptosis-related proteins (BAX, Bcl-2, P53, Cleaved PARP, Cleaved Caspase-3).
  • Lysosomal and Autophagy Assays:
    • Laser Confocal Microscopy: Used to visualize the co-localization of M1-8 with lysosomes (using LysoTracker Red) and mitochondria (using MitoTracker Red CMXRos).
  • Fluorescence Microscopy: Examined lysosomal integrity and the distribution of lysosomal protease cathepsin D.
  • Transmission Electron Microscopy (TEM): Provided ultrastructural details of HepG2 cells, observing changes in organelles and autophagosome formation.
  • Quantitative Reverse Transcription PCR (qPCR): Measured the mRNA expression of autophagy-related genes (Beclin, TSC1).
  • Autophagic Flux Analysis: Utilized a Beyotime Autophagy Tandem Sensor Ad-mCherry-GFP-LC3B Kit to assess the formation and turnover of autolysosomes.
  • In Vivo Studies: Xenograft models using nude mice were established to evaluate M1-8's anti-tumor efficacy, monitoring tumor growth, body weight, and performing histological analysis of major organs and tumor tissues.
  • Immunohistochemistry (IHC): Assessed the expression of P53 and Caspase-3 in tumor tissues.

Datasets

Not discussed in the paper. The study primarily uses established human cancer cell lines (HepG2) and normal cell lines (L02, Chang liver) for in vitro experiments and xenograft models in nude mice for in vivo studies.

Key Insights and Ideas

  • M1-8 as a Lysosome-Targeting Agent: The peptide M1-8 demonstrates a strong affinity for lysosomes, accumulating within them after cellular uptake. This targeted accumulation is a key aspect of its mechanism.
  • Lysosomal Disruption and Cathepsin D Release: M1-8 appears to disrupt lysosomal integrity, leading to the leakage of lysosomal protease cathepsin D into the cytosol. This release is hypothesized to initiate or contribute to apoptosis.
  • Inhibition of Autophagosome-Lysosome Fusion: A crucial finding is that M1-8 inhibits the fusion of autophagosomes with lysosomes, leading to an accumulation of autophagosomes and a blockage in autophagic flux. This is a novel mechanism for inducing cell death.
  • Dual Role of Autophagy Inhibition: The study suggests that while autophagy is often a survival mechanism for cancer cells, its inhibition at the fusion stage, leading to accumulation of cellular waste, can paradoxically trigger cell death.
  • Synergistic Potential: The findings suggest that M1-8 could be a valuable agent, potentially used alone or in combination with other therapies, to combat liver cancer.

Key Results

  • Inhibition of Proliferation, Migration, and Invasion: M1-8 significantly suppressed the proliferation, migration, and invasion of HepG2 liver cancer cells in a dose-dependent manner. It showed minimal toxicity to normal liver cells.
  • Induction of Apoptosis: M1-8 treatment led to a significant increase in apoptosis in HepG2 cells, evidenced by increased Annexin V+/PI+ cells, nuclear fragmentation, decreased mitochondrial membrane potential, and altered expression of pro- and anti-apoptotic proteins (increased BAX, P53, Cleaved PARP, Cleaved Caspase-3; decreased Bcl-2).
  • Lysosomal Accumulation and Rupture: Confocal microscopy confirmed M1-8's accumulation in lysosomes. Lysosomal staining intensity decreased with increasing M1-8 concentration, suggesting lysosomal rupture.
  • Autophagy Blockade: M1-8 treatment led to increased LC3-II protein expression and P62 accumulation, indicative of autophagosome formation. However, further analysis showed that M1-8 inhibited autophagosome-lysosome fusion, blocking autophagic flux.
  • In Vivo Efficacy: In a nude mouse xenograft model, M1-8 significantly inhibited tumor growth and reduced tumor weight compared to the control group, without causing substantial damage to major organs.

Limitations and Future Work

  • Mechanism of Cathepsin D Action: While the release of cathepsin D is observed, the precise molecular mechanisms by which it contributes to apoptosis (e.g., conversion of unknown substances to free radicals, direct attack on organelles) require further investigation.
  • Identification of Unknown Substances: The paper hypothesizes that released cathepsin D may convert unknown substances into bioactive molecules. Identifying these substances is a crucial next step.
  • Multiple Pathway Involvement: The authors acknowledge that while lysosomal disruption is a primary finding, other pathways might also be involved in M1-8-induced cell death.
  • In Vivo Organ Damage: While M1-8 did not cause considerable damage to major organs, further detailed toxicological studies would be beneficial for clinical translation.
  • Clinical Translation: Further research is needed to optimize M1-8 for clinical application, including studies on pharmacokinetics, pharmacodynamics, and potential drug resistance mechanisms. The development of M1-8 as a therapeutic agent for liver cancer requires extensive preclinical and clinical validation.

Summary updated

Abstract

Lysosomes, a central regulator of autophagy, play a critical role in tumour growth. Lysosomal protease cathepsin D can initiate apoptosis when released from lysosomes into the cytosol. In this study, we observed that Musca domestica cecropin (Mdc) 1-8 (M1-8), a small anti-tumour peptide derived from Mdc, inhibits hepatoma cell growth by blocking autophagy-lysosome fusion. This effect is likely achieved by targeting lysosomes to activate lysosomal protease D. Additionally, we examined whether lysosomal content and cathepsin D release were involved in M1-8-induced apoptosis. After exposure to M1-8, human hepatoma HepG2 cells rapidly co-localized with lysosomes, disrupted lysosomal integrity, caused leakage of lysosomal protease cathepsin D, caspase activation and mitochondrial membrane potential changes; and promoted cell apoptosis. Interestingly, in M1-8-treated HepG2 cells, autophagic protein content increased and the lysosome-autophagosome fusion was inhibited, suggesting that M1-8 can cause apoptosis through autophagy and lysosomes. This result indicates that a small accumulation of autophagy and autolysosome inhibition in cells can cause cell death. Taken together, these data suggest a novel insight into the regulatory mechanisms of M1-8 in autophagy and lysosomes, which may facilitate the development of M1-8 as a potential cancer therapeutic agent.
BibTeX
@article{zeng2023novel,
  author = {Jiali Zeng and Jian Wang and Jibin Wu and Rui Deng and Lun Zhang and Qingru Chen and Jie Wang and Xiaobao Jin and Shuiqing Gui and Yinghua Xu and Xuemei Lu},
  title = {{A novel antimicrobial peptide <scp>M1</scp>‐8 targets the lysosomal pathway to inhibit autolysosome formation and promote apoptosis in liver cancer cells}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2023},
  doi = {10.1111/jcmm.17644},
}
Figure